Home > Insider Trading > Filing (0001062993-23-022368)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1042074	Cymabay Therapeutics Inc.	CBAY	Pharmaceutical Preparations (2834)	943103561

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1588861	Sujal Shah	C/O Cymabay Therapeutics, Inc. 7575 Gateway Blvd., Suite 110 Newark CA 94560	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-12-11	63,975	$5.00	235,276	No	4	M	Direct
Common Stock	Disposition	2023-12-11	63,975	$19.99	171,301	No	4	S	Direct
Common Stock	Acquisiton	2023-12-11	890	$5.00	172,191	No	4	M	Direct
Common Stock	Disposition	2023-12-11	890	$20.81	171,301	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2023-12-11	31,036	$0.00	31,036	$5.00
Common Stock	Stock Appreciation Right	Disposition	2023-12-11	12,973	$0.00	12,973	$5.00
Common Stock	Employee Stock Option (right to buy)	Disposition	2023-12-11	20,856	$0.00	20,856	$5.00

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2023-12-22	No	4	M	Direct
2023-12-22	No	4	M	Direct
2024-01-05	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.78 to $20.56, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vested over a four-year period, with one-third of the shares subject to the option vesting on the grant date of December 23, 2013, and the remaining 2/3 of the shares subject to the option vesting ratably on a monthly basis over the 48 months thereafter.
The award was granted under the CymaBay 2013 Equity Incentive Plan and can be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The award vested in full on the two-year anniversary of the grant date.
The option vested over a four-year period, with one-third of the shares subject to the Option vesting on the grant date of January 6, 2014, and the remaining 2/3 of the shares subject to the Option vesting ratably on a monthly basis over the 48 months.